English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recommendations for lupus nephritis (LN) management specify that the therapeutic target should be a complete renal response (CR) [1], defined as a urine protein:Cr ratio (UPCR) of 0.5 g/gCr (50 mg/mmol) and normal or near-normal renal function. Earlier studies suggested that patients who achieved CR experienced fewer renal flares than those who achieved partial remission, defined as a 50% reduction of proteinuria [2]. Among patients who achieved CR (less than 0.50 g/gCr of UPCR), however, the renal outcome of those who achieved a value below the normal UPCR limit of 0.15 g/gCr was unclear. We recently reported that an early renal response may predict a good renal or systemic outcome [3, 4]. In this study, we investigated whether it is beneficial to achieve deep remission early by evaluating flare rate, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), cumulative glucocorticoid dose, and eGFR level. We retrospectively assessed 69 patients with biopsyproven LN class III or IV who achieved CR in our hospital. We divided them into two groups based on whether deep remission was achieved, defined as less than 0.15 g/gCr UPCR, and compared cumulative flare rates [1], defined as estimated glomerular filtration rate (eGFR) decreasing by ≥ 10%, active urine sediment, or increasing UPCR > 1.0 g/gCr after achieving CR. Furthermore, we analyzed the additional effect of early achievement of CR, defined as CR within 3 months after induction therapy. Clinical characteristics between the two groups were compared using the non-parametric Mann-Whitney U-test. Frequencies of clinicopathological characteristics were compared using the Chi-square test. Cumulative flare free rates were calculated using the Kaplan-Meier method, and differences between the two groups were tested with a log-rank test. To identify independent parameters that predict CR at 3 years, we performed multivariate analysis. During the 3-year period, 55 of 69 CR patients achieved deep remission while 14 did not. Among clinical features at baseline, the proportion of females was significantly higher among patients with deep remission (p = 0.01; Table 1). We found a significantly higher flare-free rate among patients who achieved deep remission compared with those who did not (p = 0.001; Fig. 1a). For patients with deep remission, those with early CR had a higher flare-free rate than those without (p = 0.04) (Fig. 1b), but significant difference was found in those with non-deep remission (Fig. 1c). Multivariate analysis to predict sustained CR indicated that early achievement of deep remission was an independent factor (odds ratio 3.62, 95% confidence interval 1.1– 18.9, p = 0.05). Regarding SDI, cumulative glucocorticoid dose, and eGFR level at year 3, patients with early deep remission had the most favorable result compared to the other groups (Fig. 2). In this study, we found that achieving early and deep remission predicts a good renal outcome in patients with LN class III or IV. Since renal flare predicts a worse prognosis [5], determining the method of treatment to ensure long-term maintenance of CR is challenging. Our results suggest that deep remission might be a more beneficial therapeutic goal than that of the EULAR/ERA-EDTA recommendations regarding the prevention of renal flare. A future multi-center, prospective study is required to confirm our findings.

Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV